Novavax Global Commercial Operations and COVID-19 Vaccine Update

Local events in adolescents similar to young adults, regardless of dose PREVENT-19 PRE-fusion Protein Subunit Vaccine Efficacy Novavax Trial | COVID-19 Dose 1 Grade 1-2 Grade 3+ Pain / Tenderness 63% Erythema 76% Swelling 12-17 18-25 1% 12-17 0.7% 18-25 1% 12-17 0.9% 18-25 89% Dose 2 75% 12-17 18-25 8% 6% 8% 6% 12-17 18-25 12-17 18-25 © 2023 NOVAVAX. All rights reserved. 39 novavax Includes events reported Day 0 to Day 6 post-vaccination; Grades based on FDA guidance

View entire presentation